The Asia Pacific Glycated Albumin Assay Market would witness market growth of 9.2% CAGR during the forecast period (2023-2030).
Diabetic people have higher levels of protein glycation than non-diabetic patients, glycated proteins can be utilized as a measure of glycemic management. Short-term and postprandial plasma glucose variations are reliably reflected by glycated albumin (GA). Since the glycated albumin assay technique is used to diagnose diabetes, the rising prevalence of the disease is anticipated to fuel market expansion over the coming years. For example, a study by the National Center for Biotechnology Information (NCBI) in October 2021 said that the prevalence of diabetes in India increased from 7.1% in 2009 to 8.9% in 2019.
The market will also profit from the aging populations in developed and developing nations. As the senior population is predicted to increase significantly, it is anticipated that age-related ailments, including diabetes and pancreatic problems, will become significantly more common. Diagnosing and managing such conditions result in many test prescriptions to measure levels of creatinine, albumin, glucose, ketones, and bilirubin, which drives the market's growth.
The prevalence of obesity & overweight, both of which are risk factors for Type 2 diabetes, is increasing in China as a result of bad diets and a lack of exercise. In China, 7% of adults are obese and more than a third are overweight. Children in China are also at risk for developing diabetes as a result of their unhealthy lifestyles, as more than 4 in 5 teenagers between the ages of 11 and 17 do not engage in enough physical exercise, and the prevalence of childhood obesity and overweight is rising quickly. China has the greatest prevalence of Diabetes, as reported by the seventh edition of the International Diabetes Federation (IDF) Diabetes Atlas (11.43 cr.). China has the largest incidence of Diabetes, predominantly type 2, among all nations (114 million), with type 2 being the majority. The high rate of Diabetes will create enormous growth opportunities for market.
The China market dominated the Asia Pacific Glycated Albumin Assay Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $27,799.2 Thousands by 2030. The Japan market is registering a CAGR of 8.5% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 9.9% during (2023 - 2030).
Based on Application, the market is segmented into Type 2 Diabetes, Type 1 Diabetes, and Prediabetes. Based on End User, the market is segmented into Hospitals & Diabetic Care Center, Diagnostic Laboratory, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Glycated Albumin Assay Market is Projected to reach USD 384.5 Million by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Asahi Kasei Pharma Corporation (Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.
By Application
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 